Online citations, reference lists, and bibliographies.
← Back to Search

Expression Of A Multidrug Resistance Gene In Human Cancers.

L. Goldstein, H. Galski, A. Fojo, M. Willingham, S. Lai, A. Gazdar, R. Pirker, A. Green, W. Crist, G. Brodeur
Published 1989 · Biology, Medicine

Save to my Library
Download PDF
Analyze on Scholarcy Visualize in Litmaps
Share
Reduce the time it takes to create your bibliography by a factor of 10 by using the world’s favourite reference manager
Time to take this seriously.
Get Citationsy
Many cancers have been cured by chemotherapeutic agents. However, other cancers are intrinsically drug resistant, and some acquire resistance following chemotherapy. Cloning of the cDNA for the human MDR1 gene (also known as PGY1), which encodes the multidrug efflux protein P-glycoprotein, has made it possible to measure levels of MDR1 RNA in human cancers. We report the levels of MDR1 RNA in greater than 400 human cancers. MDR1 RNA levels were usually elevated in untreated, intrinsically drug-resistant tumors, including those derived from the colon, kidney, adrenal gland, liver, and pancreas, as well as in carcinoid tumors, chronic myelogenous leukemia in blast crisis, and cell lines of non-small cell carcinoma of the lung (NSCLC) with neuroendocrine properties. MDR1 RNA levels were occasionally elevated in other untreated cancers, including neuroblastoma, acute lymphocytic leukemia (ALL) in adults, acute nonlymphocytic leukemia (ANLL) in adults, and indolent non-Hodgkin's lymphoma. MDR1 RNA levels were also increased in some cancers at relapse after chemotherapy, including ALL, ANLL, breast cancer, neuroblastoma, pheochromocytoma, and nodular, poorly differentiated lymphoma. Many types of drug-sensitive and drug-resistant tumors, including NSCLC and melanoma, contained undetectable or low levels of MDR1 RNA. The consistent association of MDR1 expression with several intrinsically resistant cancers and the increased expression of the MDR1 gene in certain cancers with acquired drug resistance indicate that the MDR1 gene contributes to multidrug resistance in many human cancers. Thus, evaluation of MDR1 gene expression may prove to be a valuable tool in the identification of individuals whose cancers are resistant to specific agents. The information may be useful in designing or altering chemotherapeutic protocols in these patients.



This paper is referenced by
10.3390/molecules26071850
Modifications of Plasma Membrane Organization in Cancer Cells for Targeted Therapy
A. Choromańska (2021)
10.1039/d0cs01061h
Stimulus-cleavable chemistry in the field of controlled drug delivery.
Yufei Xue (2021)
10.3390/pharmaceutics13060890
Cell-Penetrating Peptides: Applications in Tumor Diagnosis and Therapeutics
J. Stiltner (2021)
10.3390/ph14020107
Heat Shock Protein Inhibitor 17-Allyamino-17-Demethoxygeldanamycin, a Potent Inductor of Apoptosis in Human Glioma Tumor Cell Lines, Is a Weak Substrate for ABCB1 and ABCG2 Transporters
N. Pastvova (2021)
10.1016/j.drup.2020.100742
Taxanes in cancer treatment: Activity, chemoresistance and its overcoming.
L. Mosca (2021)
10.1016/j.spinee.2021.04.021
Chondrosarcoma of the Spine: A Narrative Review.
Zach Pennington (2021)
10.7717/peerj.9560
Silencing of the ARK5 gene reverses the drug resistance of multidrug-resistant SGC7901/DDP gastric cancer cells
Hongtao Wan (2020)
10.5772/intechopen.92712
Flavonoid-Mediated Modulation of CYP3A Enzyme and P-Glycoprotein Transporter: Potential Effects on Bioavailability and Disposition of Tyrosine Kinase Inhibitors
M. Iqbal (2020)
10.1021/acs.molpharmaceut.0c00075
Monoclonal antibody 2C5-modified mixed dendrimer micelles for tumor-targeted co-delivery of chemotherapeutics and siRNA.
Jiayi Pan (2020)
10.1016/j.euf.2020.09.007
Comprehensive Analysis of the ATP-binding Cassette Subfamily B Across Renal Cancers Identifies ABCB8 Overexpression in Phenotypically Aggressive Clear Cell Renal Cell Carcinoma.
Iulia Blajan (2020)
10.3389/fgene.2020.00516
MDR1 Gene Polymorphisms and Its Association With Expression as a Clinical Relevance in Terms of Response to Chemotherapy and Prognosis in Ovarian Cancer
A. Haque (2020)
10.1016/j.biopha.2020.110434
Low dose HSP90 inhibition with AUY922 blunts rapid evolution of metastatic and drug resistant phenotypes induced by TGF-β and paclitaxel in A549 cells.
Nickolas A. Bacon (2020)
10.1002/jcp.30063
The oncogenic potential of NANOG: An important cancer induction mediator
Basira Najafzadeh (2020)
10.3390/cells9102281
Aberrant DNA Methylation of ABC Transporters in Cancer
Katja Zappe (2020)
10.2174/1871520620666200516144403
Benzophenone Sulfonamide Derivatives as Interacting Partners and Inhibitors of Human P-glycoprotein.
S. Farman (2020)
10.1016/j.bmc.2018.12.042
Caged-xanthone from Cratoxylum formosum ssp. pruniflorum inhibits malignant cancer phenotypes in multidrug-resistant human A549 lung cancer cells through down-regulation of NF-κB.
Chutima Kaewpiboon (2019)
10.2217/nnm-2019-0024
Assembly simulation and synergistic chemotherapy of TPGS derivative functionalized polymersomes in hepatocellular carcinoma.
Tengfei Liu (2019)
10.1002/jcb.29157
Estimation of ABCB1 concentration in plasma membrane
P. Mlejnek (2019)
10.1530/ERC-18-0500
MDR1 inhibition increases sensitivity to doxorubicin and etoposide in adrenocortical cancer.
S. Creemers (2019)
10.1007/978-3-030-01775-0_2
Biological Events and Barriers to Effective Delivery of Cancer Therapeutics
E. Bozeman (2019)
Reversal of P-Glycoprotein and Breast Cancer Resistance Protein Mediated Multidrug Resistance In Vitro Using In Silico Identified Novel Compounds
A. Nanayakkara (2019)
10.1194/jlr.M091876
Acid ceramidase promotes drug resistance in acute myeloid leukemia through NF-κB-dependent P-glycoprotein upregulation
Su-Fern Tan (2019)
10.3390/ijms20174095
Chk1 Inhibitor MK-8776 Restores the Sensitivity of Chemotherapeutics in P-glycoprotein Overexpressing Cancer Cells
Qingbin Cui (2019)
10.1016/j.cbi.2019.108892
P-glycoprotein modulates oleanolic acid effects in hepatocytes cancer cells and zebrafish embryos.
Maya Kayouka (2019)
10.1007/s10822-019-00253-5
Prediction of P-glycoprotein inhibitors with machine learning classification models and 3D-RISM-KH theory based solvation energy descriptors
V. K. Hinge (2019)
10.1038/s41598-019-52490-1
A Study Comparing the Effects of Targeted Intra-Arterial and Systemic Chemotherapy in an Orthotopic Mouse Model of Pancreatic Cancer
M. Rezaee (2019)
10.1002/mc.22996
Doxorubicin induces prostate cancer drug resistance by upregulation of ABCG4 through GSH depletion and CREB activation: Relevance of statins in chemosensitization
Sreevidya Mallappa (2019)
10.25258/IJDDT.9.4.15
Stem Cell Factor Antibody: Effective Manipulation of Antihormonal Therapy in Resistant Human Breast Cancer In Vitro
K. Arif (2019)
10.1016/j.ejpb.2019.01.006
Polyamidoamine dendrimers‐based nanomedicine for combination therapy with siRNA and chemotherapeutics to overcome multidrug resistance
Jiayi Pan (2019)
10.21873/anticanres.13277
P-Glycoprotein Overexpression Is Associated With Cisplatin Resistance in Human Osteosarcoma
C. He (2019)
10.1186/s12943-019-1114-z
Chemotherapeutic drugs stimulate the release and recycling of extracellular vesicles to assist cancer cells in developing an urgent chemoresistance
Xiao-kun Wang (2019)
10.1002/9781119060208.CH4
Signal Transduction in Disease
P. Ganey (2019)
See more
Semantic Scholar Logo Some data provided by SemanticScholar